Could Early Tirzepatide Alter the Course of Type 2 Diabetes?

— SUPPRESS-EARLY trial shows multiple benefits over intensive conventional therapy

by Gregory Laub, Senior Director, Video, MedPage Today

June 29, 2026

• 3 min read

At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.